description AbbVie (ABBV) Overview
AbbVie is a pharmaceutical company recognized for its portfolio of innovative therapies across immunology, oncology, and neurology. It’s notable as a dividend aristocrat, consistently increasing shareholder payouts. The company provides medications primarily for patients needing treatment in these specialized healthcare areas. Investors seeking stable income from established pharmaceutical holdings often consider AbbVie.
help AbbVie (ABBV) FAQ
What is AbbVie's most famous pharmaceutical drug?
AbbVie is best known for Humira (adalimumab), which was historically the world's best-selling prescription drug, generating billions in annual revenue. Following the loss of its patent exclusivity, AbbVie has heavily shifted its focus to successor drugs like Skyrizi and Rinvoq.
Is AbbVie considered a reliable dividend stock?
Yes, AbbVie (ABBV) is highly regarded as a Dividend King because it has increased its dividend payout for over 50 consecutive years. The stock typically offers a high dividend yield compared to the broader market, though it inherited this streak from its former parent company, Abbott Laboratories.
When did AbbVie spin off from Abbott Laboratories?
AbbVie was officially spun off from Abbott Laboratories on January 1, 2013, to separate its research-based pharmaceutical business. The split allowed AbbVie to focus entirely on developing biologic therapies outside of Abbott's diversified medical devices and diagnostics.
What therapeutic areas does AbbVie primarily focus on?
AbbVie primarily generates revenue by developing and commercializing therapies in the fields of immunology, oncology, neuroscience, and virology. Their research pipeline is heavily focused on autoimmune conditions like rheumatoid arthritis and Crohn's disease.
explore Explore More
Similar to AbbVie (ABBV)
See all arrow_forward
Reviews & Comments
Write a Review
Be the first to review
Share your thoughts with the community and help others make better decisions.
